- Home
- MNTSW vs MRK Comparison
MNTSW vs MRK Comparison
Compare MNTSW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNTSW | MRK |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | 123 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 260.2B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNTSW | MRK |
|---|---|---|
| Price | $0.02 | $100.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $111.93 |
| AVG Volume (30 Days) | N/A | ★ 15.2M |
| Earning Date | N/A | 02-03-2026 |
| Dividend Yield | N/A | ★ 3.43% |
| EPS Growth | N/A | ★ 58.08 |
| EPS | N/A | ★ 7.56 |
| Revenue | N/A | ★ $64,235,000,000.00 |
| Revenue This Year | N/A | $1.97 |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | ★ N/A | $13.13 |
| Revenue Growth | N/A | ★ 1.68 |
| 52 Week Low | N/A | $73.31 |
| 52 Week High | N/A | $105.84 |
Technical Indicators
Market Signals| Indicator | MNTSW | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 59.73 |
| Support Level | $0.02 | $96.79 |
| Resistance Level | $0.05 | $100.94 |
| Average True Range (ATR) | 0.01 | 2.42 |
| MACD | 0.00 | -0.55 |
| Stochastic Oscillator | 23.32 | 50.03 |
Price Performance
Historical ComparisonAbout MNTSW Momentus Inc. Warrant
Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions, in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).